SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

SELLAS Life Sciences Group, Inc. (SLS) Healthcare & Pipeline Overview

SELLAS Life Sciences Group is a biopharmaceutical company specializing in cancer immunotherapies, with its lead candidate, galinpepimut-S (GPS), undergoing Phase III trials for acute myeloid leukemia and Phase 1/2 trials for ovarian cancer. The company also develops nelipepimut-S for early-stage breast cancer and collaborates with Merck.

What Is the Investment Thesis for SLS?

SELLAS Life Sciences Group presents a focused investment opportunity within the biotechnology sector, driven by its late-stage clinical pipeline. The primary value driver is the potential success of galinpepimut-S (GPS) in treating acute myeloid leukemia (AML), currently in Phase III trials. Positive trial outcomes could lead to significant market penetration, given the unmet need in AML treatment. The collaboration with Merck to evaluate GPS in combination with pembrolizumab provides additional upside potential across multiple cancer indications. However, the company's success is contingent on navigating regulatory hurdles and securing FDA approval for its lead candidates. With a market cap of $2.51B and a beta of 2.23, SELLAS exhibits higher volatility, reflecting the inherent risks associated with clinical-stage biopharmaceutical companies.

Based on FMP financials and quantitative analysis

SLS Key Highlights

Galinpepimut-S (GPS) is in Phase III clinical trials for the treatment of acute myeloid leukemia (AML).

• Nelipepimut-S is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
• Strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with pembrolizumab.
• The company was founded in 2012 and is headquartered in New York, New York.
• SELLAS has a market capitalization of $2.51B.

Who Are SLS's Competitors?

SLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SLS's Key Strengths?

Late-stage clinical pipeline with GPS in Phase III trials.

• Targeted immunotherapy approach focusing on specific cancer antigens.
• Strategic collaboration with Merck & Co., Inc.
• Experienced management team.

What Are SLS's Weaknesses?

Limited financial resources compared to larger pharmaceutical companies.

• Dependence on the success of its lead product candidates.
• Small number of employees (15).
• High beta of 2.23 indicates high volatility.

What Could Drive SLS Stock Higher?

SLS catalyst: Data readout from Phase III clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).

• Interim data from Phase 1/2 clinical trial of GPS in ovarian cancer.
• Data readout from Phase 2b clinical trial of nelipepimut-S in early-stage breast cancer.
• Enrollment and progress in the Phase 1/2 clinical trial evaluating GPS in combination with pembrolizumab.

What Are the Key Risks for SLS?

Negative return on equity (-35.9%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to meet primary endpoints in clinical trials.
• Regulatory setbacks and delays in obtaining FDA approval.
• Competition from other cancer immunotherapy companies.
• Dependence on key personnel and the ability to retain talent.
• Limited financial resources and the need to raise additional capital.

What Are the Growth Opportunities for SLS?

• Galinpepimut-S (GPS) for Acute Myeloid Leukemia (AML): The Phase III clinical trials for GPS in AML represent a significant growth opportunity for SELLAS. The AML market is projected to reach $3.8 billion by 2028, driven by the increasing incidence of AML and the demand for more effective treatments. Positive trial results and subsequent regulatory approval could enable SELLAS to capture a substantial share of this market. The timeline for potential approval is estimated within the next 2-3 years, pending successful trial outcomes and regulatory review.
• Galinpepimut-S (GPS) for Ovarian Cancer: The Phase 1/2 clinical trials for GPS in ovarian cancer offer another avenue for growth. Ovarian cancer remains a challenging disease with high unmet needs, and novel immunotherapies could offer improved outcomes. The ovarian cancer therapeutics market is expected to reach $6.7 billion by 2027. Successful trial results could position GPS as a valuable treatment option, expanding SELLAS's market reach. The timeline for potential approval is estimated within the next 3-5 years.
• Nelipepimut-S for Early-Stage Breast Cancer: The Phase 2b clinical trials for nelipepimut-S in early-stage breast cancer represent a targeted growth opportunity. HER2-positive breast cancer is a well-defined market segment, and effective immunotherapies could improve patient outcomes and reduce recurrence rates. The breast cancer therapeutics market is projected to reach $30 billion by 2028. Positive trial results could lead to regulatory approval and commercialization, driving revenue growth for SELLAS. The timeline for potential approval is estimated within the next 3-5 years.
• Combination Therapy with Pembrolizumab: The strategic collaboration with Merck to evaluate GPS in combination with pembrolizumab across multiple cancer indications provides a broad growth opportunity. Combination therapies are increasingly recognized as a promising approach to enhance the efficacy of cancer treatments. Successful trial results could lead to the expansion of GPS's applications and increased market penetration. The timeline for potential approval varies depending on the specific cancer indications and trial outcomes.
• Expansion into New Cancer Indications: SELLAS has the potential to expand its pipeline and target new cancer indications beyond AML, ovarian cancer, and breast cancer. The company's expertise in developing cancer immunotherapies targeting specific antigens could be leveraged to address other unmet needs in oncology. Strategic partnerships, acquisitions, or internal research and development efforts could drive this expansion. The timeline for potential new product launches is dependent on the specific indications and development timelines.

What Threats Does SLS Face?

• Clinical trial failures and regulatory setbacks.
• Competition from other cancer immunotherapy companies.
• Patent expirations and loss of exclusivity.
• Changes in healthcare regulations and reimbursement policies.

What Are SLS's Competitive Advantages?

• Proprietary cancer immunotherapy technology targeting specific cancer antigens.
• Late-stage clinical pipeline with galinpepimut-S (GPS) in Phase III trials.
• Strategic collaboration with Merck & Co., Inc.
• Experienced management team with expertise in cancer immunotherapy development.

What Does SLS Do?

Founded in 2012 and headquartered in New York City, SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company dedicated to the development of innovative cancer immunotherapies. The company's primary focus is on addressing various cancer indications through targeted therapeutic interventions. SELLAS's lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent targeting Wilms tumor 1 (WT1), a protein overexpressed in a variety of cancers. GPS is currently in Phase III clinical trials for the treatment of acute myeloid leukemia (AML) and in Phase 1/2 clinical trials for ovarian cancer. Additionally, SELLAS is developing nelipepimut-S, a cancer immunotherapy targeting human epidermal growth factor receptor 2 (HER2), which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. SELLAS has a strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with pembrolizumab, a PD-1 blocker, in a Phase 1/2 clinical trial across multiple cancer indications, including hematologic malignancies and solid tumors. This collaboration underscores SELLAS's commitment to advancing cancer treatment through strategic partnerships and innovative research.

What Products and Services Does SLS Offer?

• Develops cancer immunotherapies for various cancer indications.
• Focuses on therapies targeting Wilms tumor 1 (WT1) and human epidermal growth factor receptor 2 (HER2).
• Conducts Phase III clinical trials for galinpepimut-S (GPS) in acute myeloid leukemia (AML).
• Conducts Phase 1/2 clinical trials for GPS in ovarian cancer.
• Conducts Phase 2b clinical trials for nelipepimut-S in early-stage breast cancer.
• Collaborates with Merck & Co., Inc. to evaluate GPS in combination with pembrolizumab.

How Does SLS Make Money?

• Develops and patents novel cancer immunotherapies.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Seeks regulatory approval from the FDA and other regulatory agencies.
• Commercializes approved products through sales and marketing efforts, or through partnerships.

What Industry Does SLS Operate In?

SELLAS Life Sciences operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer immunotherapies is rapidly expanding, driven by advances in understanding the role of the immune system in fighting cancer. Key trends include the development of personalized therapies, combination therapies, and novel drug delivery systems. SELLAS's focus on targeting specific cancer antigens like WT1 and HER2 positions it within a niche segment of the market. The company competes with larger pharmaceutical companies and other biotechnology firms developing similar immunotherapies.

Who Are SLS's Key Customers?

• Hospitals and cancer centers.
• Oncologists and hematologists.
• Patients with acute myeloid leukemia, ovarian cancer, and breast cancer.
• Pharmaceutical companies through strategic collaborations.

Company Profile

SELLAS Life Sciences Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Angelos Stergiou. SLS has traded publicly since 2008.

Return on equity for SELLAS Life Sciences Group, Inc. stands at -35.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.

SLS Valuation & Market Position

With a $2.51B market cap, SELLAS Life Sciences Group, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $35.00 to $35.00, with a consensus of $35.00. At the current price of $13.49, that implies approximately 159% upside potential. Relative to its peer group, SLS's quantitative score of 68/100 is below the peer average of 81/100.

Quarterly Financial Performance: SELLAS Life Sciences Group, Inc.

Revenue for SELLAS Life Sciences Group, Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $9.6M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, SLS averaged $-0.05 in diluted EPS.

SELLAS Life Sciences Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

SELLAS Life Sciences Group, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 16.0% above estimates on average.

The most recent 12 insider filings for SELLAS Life Sciences Group, Inc. break down as 3 sales and 9 purchases. On net that is roughly 1.7M shares acquired (about $363K) — insiders putting money in tends to read as conviction.

SLS Financials

SLS Latest News

SLS Analyst Consensus

SLS MoonshotScore

SLS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources